Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.45 |
| ▸ | CCR3 | P51677 | 3/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.43 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19764427 | 0.86 | KDM4E (0.61) | KDM1AKDM4ECHRM4CCR3 | |
| SCHEMBL12814152 | 0.86 | KDM1A (0.53) | KDM1ADRD2DRD4KDM4ECHRM4 | |
| SCHEMBL20843153 | 0.86 | KDM1A (0.53) | KDM1ADRD2DRD4KDM4ECHRM4 | |
| SCHEMBL17987974 | 0.85 | KDM1A (0.52) | KDM1ADRD2DRD4KDM4ECHRM4 | |
| SCHEMBL20843229 | 0.85 | KDM1A (0.52) | KDM1ADRD2DRD4KDM4ECHRM4 | |
| SCHEMBL20843175 | 0.83 | KDM1A (0.58) | KDM1ADRD2DRD4KDM4ECHRM4 | |
| SCHEMBL28175300 | 0.83 | KDM4E (0.50) | KDM1ADRD2DRD4KDM4ECHRM4 | |
| SCHEMBL15033023 | 0.83 | KDM4E (0.50) | KDM1ADRD2DRD4KDM4ECHRM4 | |
| SCHEMBL19764433 | 0.82 | HRH3 (0.50) | CHRM4CCR3HRH3GAA | |
| SCHEMBL17963554 | 0.81 | KDM4E (0.55) | KDM1ADRD2DRD4KDM4EHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180009735-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180009735-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KDM1B, HDAC1, DOT1L | KDM1A 7/4885DRD2 4681/4885DRD4 4821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.